Crowley Steven D, Vasievich Matthew P, Ruiz Phillip, Gould Samantha K, Parsons Kelly K, Pazmino A Kathy, Facemire Carie, Chen Benny J, Kim Hyung-Suk, Tran Trinh T, Pisetsky David S, Barisoni Laura, Prieto-Carrasquero Minolfa C, Jeansson Marie, Foster Mary H, Coffman Thomas M
Department of Medicine, Division of Nephrology, Duke University Medical Center, and Durham VA Medical Center, Durham, North Carolina 27705, USA.
J Clin Invest. 2009 Apr;119(4):943-53. doi: 10.1172/JCI34862. Epub 2009 Mar 16.
Studies in humans and animal models indicate a key contribution of angiotensin II to the pathogenesis of glomerular diseases. To examine the role of type 1 angiotensin (AT1) receptors in glomerular inflammation associated with autoimmune disease, we generated MRL-Faslpr/lpr (lpr) mice lacking the major murine type 1 angiotensin receptor (AT1A); lpr mice develop a generalized autoimmune disease with glomerulonephritis that resembles SLE. Surprisingly, AT1A deficiency was not protective against disease but instead substantially accelerated mortality, proteinuria, and kidney pathology. Increased disease severity was not a direct effect of immune cells, since transplantation of AT1A-deficient bone marrow did not affect survival. Moreover, autoimmune injury in extrarenal tissues, including skin, heart, and joints, was unaffected by AT1A deficiency. In murine systems, there is a second type 1 angiotensin receptor isoform, AT1B, and its expression is especially prominent in the renal glomerulus within podocytes. Further, expression of renin was enhanced in kidneys of AT1A-deficient lpr mice, and they showed evidence of exaggerated AT1B receptor activation, including substantially increased podocyte injury and expression of inflammatory mediators. Administration of losartan, which blocks all type 1 angiotensin receptors, reduced markers of kidney disease, including proteinuria, glomerular pathology, and cytokine mRNA expression. Since AT1A-deficient lpr mice had low blood pressure, these findings suggest that activation of type 1 angiotensin receptors in the glomerulus is sufficient to accelerate renal injury and inflammation in the absence of hypertension.
对人类和动物模型的研究表明,血管紧张素II在肾小球疾病的发病机制中起关键作用。为了研究1型血管紧张素(AT1)受体在与自身免疫性疾病相关的肾小球炎症中的作用,我们培育出了缺乏主要的小鼠1型血管紧张素受体(AT1A)的MRL-Faslpr/lpr(lpr)小鼠;lpr小鼠会发展出一种伴有肾小球肾炎的全身性自身免疫性疾病,类似于系统性红斑狼疮。令人惊讶的是,AT1A缺陷并不能预防疾病,反而显著加速了死亡率、蛋白尿和肾脏病理变化。疾病严重程度的增加并非免疫细胞的直接作用,因为移植缺乏AT1A的骨髓并不影响生存。此外,包括皮肤、心脏和关节在内的肾外组织中的自身免疫损伤不受AT1A缺陷的影响。在小鼠系统中,存在第二种1型血管紧张素受体亚型AT1B,其表达在足细胞内的肾小球中尤为突出。此外,在缺乏AT1A的lpr小鼠的肾脏中,肾素表达增强,并且它们显示出AT1B受体激活过度的证据,包括足细胞损伤和炎症介质表达大幅增加。给予阻断所有1型血管紧张素受体的氯沙坦可降低肾脏疾病标志物,包括蛋白尿、肾小球病理变化和细胞因子mRNA表达。由于缺乏AT1A的lpr小鼠血压较低,这些发现表明,在没有高血压的情况下,肾小球中1型血管紧张素受体的激活足以加速肾损伤和炎症。